June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Predictors of response to intravitreal bevacizumab for the treatment of diabetic macula edema; preliminary results of a retrospective case series

Author Affiliations & Notes
  • Ebony Liu
    Flinders University, Adelaide, South Australia, Australia
  • Georgia Kaidonis
    Flinders University, Adelaide, South Australia, Australia
  • Stewart Lake
    Flinders University, Adelaide, South Australia, Australia
  • Kathryn P Burdon
    University of Tasmania, Hobart, Tasmania, Australia
  • Jamie E Craig
    Flinders University, Adelaide, South Australia, Australia
  • Footnotes
    Commercial Relationships   Ebony Liu, None; Georgia Kaidonis, None; Stewart Lake, None; Kathryn Burdon, None; Jamie Craig, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1901. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ebony Liu, Georgia Kaidonis, Stewart Lake, Kathryn P Burdon, Jamie E Craig; Predictors of response to intravitreal bevacizumab for the treatment of diabetic macula edema; preliminary results of a retrospective case series

      . Invest. Ophthalmol. Vis. Sci. 2017;58(8):1901.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Visual and anatomical response to intravitreal bevacizumab for the treatment of diabetic macula edema are highly variable in practice and clinical trials. We performed a retrospective case series to identify any clinical and genetic predictors of response.

Methods : 194 patients from the Registry of Advanced Diabetic Retinopathy have been genotyped and identified as having diabetic maculopathy where treatment includes intravitreal bevacizumab. Poor responders were defined as requiring more than 3 bevacizumab treatments to achieve greater than 10% change in central macula thickness from baseline.

Results : Data collection is complete for 81 patients (responders n=19, poor responders n=62). There was no significant association between responder status and gender, duration of diabetes and baseline HbA1c. Age was associated with treatment response (responders; 56+/-12 years, poor responders; 65 +/-12 years, p=0.009).

Conclusions : Initial analysis suggests systemic factors such as HbA1c and duration of diabetes are not associated with clinical response to intravitreal bevacizumab, but younger age is associated with better response. Further analysis is ongoing to confirm these findings and explore genetic associations (including haplotype and variation at the vascular endothelial growth factor genes) with treatment response.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×